Preclinical evaluation of the RBD-Trimeric vaccine: A novel approach to strengthening biotechnological sovereignty in developing countries against SARS-CoV-2 variants
New immunogens against emerging new virus variants are essential for controlling new variants. Methods: A preclinical study in which a receptor-binding domain (RBD) trimer was designed in silico with information from the Beta (B.1.351), Omicron (BA.5), and Wuhan 1 variant. A three-dimensional model...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Travel Medicine and Infectious Disease |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1477893925000262 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850189963019157504 |
|---|---|
| author | Luis Flórez Daniel Echeverri-De la Hoz Alfonso Calderón Hector Serrano-Coll Caty Martinez Camilo Guzmán Bertha Gastelbondo German Arrieta Ariel Arteta Tania Márquez Ricardo Rivero Salim Máttar |
| author_facet | Luis Flórez Daniel Echeverri-De la Hoz Alfonso Calderón Hector Serrano-Coll Caty Martinez Camilo Guzmán Bertha Gastelbondo German Arrieta Ariel Arteta Tania Márquez Ricardo Rivero Salim Máttar |
| author_sort | Luis Flórez |
| collection | DOAJ |
| description | New immunogens against emerging new virus variants are essential for controlling new variants. Methods: A preclinical study in which a receptor-binding domain (RBD) trimer was designed in silico with information from the Beta (B.1.351), Omicron (BA.5), and Wuhan 1 variant. A three-dimensional model of the RBD-trimer was made, and the synthesis of the trimer was based on the RBD domain of the S protein of Beta and Omicron. For the experimental trials, 63 BALB/c mice were immunized and divided into three groups: control (n = 15), adjuvant (n = 15), and RBD-trimer (n = 33). Results: 81 % (13/16), 90 % (9/10), and 85 % (6/7) of BALB/c mice that received one dose, two doses, and three doses, respectively, seroconverted. Significant statistical differences (p < 0.001) were found between the experimental group vaccinated with the RBD-trimer, the group with adjuvant, and the control group. The booster did not show significant differences (p > 0.05. No inflammatory or cellular changes were observed, highlighting the safety of the RBD vaccine candidate. Kinetics and seroconversion of 75 % were obtained in the mice with two doses of tri-RBD. (P < 0.0001). Conclusions: Applying two doses of the RBD vaccine candidate in BALB/c mice was safe and immunogenic against SARS-CoV-2. This study provides support for the country's biotechnological sovereignty and its potential contribution to public health in Colombia. |
| format | Article |
| id | doaj-art-2e366d515d554c668a4dd01af912839b |
| institution | OA Journals |
| issn | 1873-0442 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Travel Medicine and Infectious Disease |
| spelling | doaj-art-2e366d515d554c668a4dd01af912839b2025-08-20T02:15:28ZengElsevierTravel Medicine and Infectious Disease1873-04422025-03-016410282010.1016/j.tmaid.2025.102820Preclinical evaluation of the RBD-Trimeric vaccine: A novel approach to strengthening biotechnological sovereignty in developing countries against SARS-CoV-2 variantsLuis Flórez0Daniel Echeverri-De la Hoz1Alfonso Calderón2Hector Serrano-Coll3Caty Martinez4Camilo Guzmán5Bertha Gastelbondo6German Arrieta7Ariel Arteta8Tania Márquez9Ricardo Rivero10Salim Máttar11Instituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, ColombiaInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, ColombiaInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, ColombiaInstituto Colombiano de Medicina Tropical-Universidad CES, Medellín, ColombiaInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, ColombiaInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Facultad de Ciencias de la Salud, Universidad de Córdoba, Montería, ColombiaInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Facultad de Ciencias de la Salud, Universidad de Córdoba, Montería, ColombiaInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Grupo de Investigación en Salud Publica, Universidad, CECAR, Sincelejo, ColombiaDepartamento de Patología, Grupo de Investigaciones en Patología, Universidad de Antioquia, Medellín, ColombiaFacultad de Medicina Veterinaria, Universidad de Antioquia, Medellín, ColombiaInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Paul G. Allen School for Global Health, Washington State University, Pullman, WA, USAInstituto de Investigaciones Biológicas del Trópico, Universidad de Córdoba, Montería, Colombia; Corresponding author.New immunogens against emerging new virus variants are essential for controlling new variants. Methods: A preclinical study in which a receptor-binding domain (RBD) trimer was designed in silico with information from the Beta (B.1.351), Omicron (BA.5), and Wuhan 1 variant. A three-dimensional model of the RBD-trimer was made, and the synthesis of the trimer was based on the RBD domain of the S protein of Beta and Omicron. For the experimental trials, 63 BALB/c mice were immunized and divided into three groups: control (n = 15), adjuvant (n = 15), and RBD-trimer (n = 33). Results: 81 % (13/16), 90 % (9/10), and 85 % (6/7) of BALB/c mice that received one dose, two doses, and three doses, respectively, seroconverted. Significant statistical differences (p < 0.001) were found between the experimental group vaccinated with the RBD-trimer, the group with adjuvant, and the control group. The booster did not show significant differences (p > 0.05. No inflammatory or cellular changes were observed, highlighting the safety of the RBD vaccine candidate. Kinetics and seroconversion of 75 % were obtained in the mice with two doses of tri-RBD. (P < 0.0001). Conclusions: Applying two doses of the RBD vaccine candidate in BALB/c mice was safe and immunogenic against SARS-CoV-2. This study provides support for the country's biotechnological sovereignty and its potential contribution to public health in Colombia.http://www.sciencedirect.com/science/article/pii/S1477893925000262Public healthBiotechnologySocial developmentComputational biologyPreventive medicineVulnerable populations |
| spellingShingle | Luis Flórez Daniel Echeverri-De la Hoz Alfonso Calderón Hector Serrano-Coll Caty Martinez Camilo Guzmán Bertha Gastelbondo German Arrieta Ariel Arteta Tania Márquez Ricardo Rivero Salim Máttar Preclinical evaluation of the RBD-Trimeric vaccine: A novel approach to strengthening biotechnological sovereignty in developing countries against SARS-CoV-2 variants Travel Medicine and Infectious Disease Public health Biotechnology Social development Computational biology Preventive medicine Vulnerable populations |
| title | Preclinical evaluation of the RBD-Trimeric vaccine: A novel approach to strengthening biotechnological sovereignty in developing countries against SARS-CoV-2 variants |
| title_full | Preclinical evaluation of the RBD-Trimeric vaccine: A novel approach to strengthening biotechnological sovereignty in developing countries against SARS-CoV-2 variants |
| title_fullStr | Preclinical evaluation of the RBD-Trimeric vaccine: A novel approach to strengthening biotechnological sovereignty in developing countries against SARS-CoV-2 variants |
| title_full_unstemmed | Preclinical evaluation of the RBD-Trimeric vaccine: A novel approach to strengthening biotechnological sovereignty in developing countries against SARS-CoV-2 variants |
| title_short | Preclinical evaluation of the RBD-Trimeric vaccine: A novel approach to strengthening biotechnological sovereignty in developing countries against SARS-CoV-2 variants |
| title_sort | preclinical evaluation of the rbd trimeric vaccine a novel approach to strengthening biotechnological sovereignty in developing countries against sars cov 2 variants |
| topic | Public health Biotechnology Social development Computational biology Preventive medicine Vulnerable populations |
| url | http://www.sciencedirect.com/science/article/pii/S1477893925000262 |
| work_keys_str_mv | AT luisflorez preclinicalevaluationoftherbdtrimericvaccineanovelapproachtostrengtheningbiotechnologicalsovereigntyindevelopingcountriesagainstsarscov2variants AT danielecheverridelahoz preclinicalevaluationoftherbdtrimericvaccineanovelapproachtostrengtheningbiotechnologicalsovereigntyindevelopingcountriesagainstsarscov2variants AT alfonsocalderon preclinicalevaluationoftherbdtrimericvaccineanovelapproachtostrengtheningbiotechnologicalsovereigntyindevelopingcountriesagainstsarscov2variants AT hectorserranocoll preclinicalevaluationoftherbdtrimericvaccineanovelapproachtostrengtheningbiotechnologicalsovereigntyindevelopingcountriesagainstsarscov2variants AT catymartinez preclinicalevaluationoftherbdtrimericvaccineanovelapproachtostrengtheningbiotechnologicalsovereigntyindevelopingcountriesagainstsarscov2variants AT camiloguzman preclinicalevaluationoftherbdtrimericvaccineanovelapproachtostrengtheningbiotechnologicalsovereigntyindevelopingcountriesagainstsarscov2variants AT berthagastelbondo preclinicalevaluationoftherbdtrimericvaccineanovelapproachtostrengtheningbiotechnologicalsovereigntyindevelopingcountriesagainstsarscov2variants AT germanarrieta preclinicalevaluationoftherbdtrimericvaccineanovelapproachtostrengtheningbiotechnologicalsovereigntyindevelopingcountriesagainstsarscov2variants AT arielarteta preclinicalevaluationoftherbdtrimericvaccineanovelapproachtostrengtheningbiotechnologicalsovereigntyindevelopingcountriesagainstsarscov2variants AT taniamarquez preclinicalevaluationoftherbdtrimericvaccineanovelapproachtostrengtheningbiotechnologicalsovereigntyindevelopingcountriesagainstsarscov2variants AT ricardorivero preclinicalevaluationoftherbdtrimericvaccineanovelapproachtostrengtheningbiotechnologicalsovereigntyindevelopingcountriesagainstsarscov2variants AT salimmattar preclinicalevaluationoftherbdtrimericvaccineanovelapproachtostrengtheningbiotechnologicalsovereigntyindevelopingcountriesagainstsarscov2variants |